中国血液净化

中国血液净化 ›› 2019, Vol. 18 ›› Issue (08): 547-549.doi: 10.3969/j.issn.1671-4091.2019.08.009

• 临床研究 • 上一篇    下一篇

免疫吸附治疗强直性脊柱炎疗效观察

王凯1,李鞠1,李慧1,孟德钎1   

  1. 1. 南京医科大学附属淮安一院风湿免疫科
  • 收稿日期:2018-06-28 修回日期:2019-05-06 出版日期:2019-08-12 发布日期:2019-08-15
  • 通讯作者: 孟德钎 deqian03@126.com E-mail:deqian03@126.com

The efficacy of immunoabsorption therapy for ankylosing spondylitis

  1. 1Department of Rheumatology, Huai’an First People’s Hospital, Nanjing Medical University,Huai’an 223001, China
  • Received:2018-06-28 Revised:2019-05-06 Online:2019-08-12 Published:2019-08-15

PDF

909

摘要： 【摘要】目的观察免疫吸附治疗强直性脊柱炎(ankylosing spondylitis,AS)的疗效。方法选取AS 常规治疗组30 例和AS 免疫吸附治疗组30 例为实验对象，分别于治疗前、治疗后1 周、1 月、3 月后检测3组红细胞沉降率(erythrocyte sedimentation rate,ESR)、C 反应蛋白(C-reaction protein,CRP)，并评估Bath AS 疾病活动指数评分(Bath AS disease activity index,BASDAI)。结果①免疫吸附治疗1 周治疗组患者较对照组ESR、CRP、BASDAI 的差异有统计学意义(Z 值分别为2.692,2.511,3.866；P值分别为-0.007，0.012，＜0.001)。②免疫吸附治疗3 月后免疫吸附治疗组较对照组ESR、CRP 下降，BASDAI评分降低，差异有统计学意义(Z 值分别为2.905, 6.427, 2.000；P 值分别为0.004,＜0.001,0.045)；③治疗3 月后免疫吸附治疗组较对照组非甾体类抗炎药的用量下降，差异有统计学意义(Z =4.296,P＜0.001)。结论免疫吸附治疗AS，炎症指标恢复快，起效快，病情易于稳定。免疫吸附治疗可减轻炎症反应。

关键词: 强直性脊柱炎, 免疫吸附

Abstract:

【Abstract】Objective To investigate the efficacy of immunoadsorption therapy for ankylosing spondylitis (AS). Methods A total of 60 patients with AS were recruited and allocated into control group (n=30) or immunoadsorption group (n=30). Erythrocyte sedimentation rate (ESR), C- reaction protein (CRP) and the score of Bath AS disease activity index (BASDAI) were assessed before the treatment and at the first week, first month and 3rd month after the treatment. Results At the first week after the treatment, ESR (Z=2.692,P=-0.007), CRP (Z=2.511, P=0.012) and BASDAI score (Z=3.866, P=0.000) were significantly lower in immunoadsorption group than in control group. At the 3rd month after the treatment, ESR (Z=2.905, P=0.004), CRP (Z= 6.427, P=0.000) and BASDAI score (Z=2.000, P=0.045) were still lower in immunoadsorption group than in control group; in addition, the doses of non-steroid anti-inflammatory drugs (NSAIDs) reduced in immunoadsorption group as compared with those in control group (Z=4.296, P=0.000). Conclusion Immunoadsorption treatment for AS has the advantages of fast improvement of inflammatory biomarkers and clinical conditions with stable efficacies. Immunoadsorption therapy can also alleviate the inflammation responses in AS patients.

Key words: Ankylosing spondylitis, Immunoadsorption

中图分类号: